V
Verve Therapeutics
Focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary
About Verve Therapeutics
Verve Therapeutics is a pioneering genetic medicines company focused on transforming the treatment of cardiovascular disease through innovative gene editing technologies. The company operates in the biotechnology sector, specifically targeting cardiovascular health. Verve's business model revolves around discovering and developing single-course gene editing medicines that aim to provide long-term solutions for patients, as opposed to traditional chronic management therapies. The initial programs target the PCSK9 and ANGPTL3 genes, which are well-validated for their roles in lowering blood lipid levels. Verve Therapeutics primarily serves patients suffering from cardiovascular diseases, offering them potentially curative treatments. The company generates revenue through the development and commercialization of its gene editing therapies, as well as potential partnerships and collaborations with other biotech firms and healthcare providers.
Source: Dealroom company dataLatest news
Press, funding announcements and product moves mentioning Verve Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A14 investors entered at this stage
Biomatics Capital Partners
ARCH Venture Partners
GV
Casdin Capital
F-Prime
Wellington Management
Redmile Group
Cormorant Asset Management
RA Capital Management
Janus Henderson Investors
Logos Capital
Rock Springs Capital
Novo Holdings
Citadel
Series B and later1 investor entered at this stage
Eli Lilly
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
11 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Verve Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Verve Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.